CD8A and plasma cell myeloma: Furthermore, this study showed that the treatment of immunocompetent myeloma models with DCZ0415 increases the numbers of immune cells (CD3, CD4 and CD8) and inhibits nuclear factor kappa B (NF‐κB) activity, suggesting the immunotherapeutic value of inhibiting TRIP13 [26].